Weight loss with a lower dose compounded semaglutide and behavioral weight management program: A real-world matched retrospective cohort study

Objective: This 16-week, real-world retrospective cohort study of a behavioral weight management program evaluated the efficacy of a lower dose of compounded semaglutide on weight loss. Methods: Weight loss was compared among Noom Weight (NW) users, Noom Microdose GLP-1 Rx Program (NMGP) users prescribed a low dose of compounded semaglutide (up to 0.6mg/weekly), and Noom GLP-1 Rx Program (NGP) users prescribed a dose up to 1.2mg/weekly of compounded semaglutide via multiple-group latent growth curve models for the full sample and propensity score matched cohort. Users were matched on demographic characteristics, Area Deprivation Index, baseline Body Mass Index, and urbanicity. Results: In the full sample, participants (N = 29,788) were mostly middle-aged, urban-dwelling females. At 16 weeks, NW users lost 2.6%, NMGP users lost 8.3%, and NGP users lost 8.6% of their baseline weight (all comparisons p [&le;] .001). In the matched cohort (N = 3,657; n= 1,219 per group), participant characteristics were similar. At 16 weeks, NW users lost 2.6%, NMGP users lost 8.3%, and NGP users lost 9.1% of their initial weight (all comparisons p < .001). Conclusions: This large, retrospective cohort reports lower doses of compounded semaglutide alongside a behavioral companion achieve 91% of the weight loss of a higher dose of compounded semaglutide in the first 16 weeks.